VTYX   $2.5300000000000002  3.27% Market Closed After Close 2.5 -1.19%

Ventyx Biosciences Inc
Last Events:

2023-11-07 The hottest instrument.

2023-10-09 The hottest instrument.

2023-08-09 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-06 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-06 Signal in EMA50 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-06 Trend Power changed from to medium strength.

2023-08-05 Trend pattern changed from расходящийся треугольник to канал.

2023-08-05 Signal in MACD changed from bullish weakening to bearish reversal. Oscillator MACD is in the positive territory it crossed the signal line from the top and falls. These factors mean that the market confirms the end of the upward trend. Last signal: main and signal line crossing.


Current temperature: 4.27
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 9
Target Price Mean 10.00
Mean unverified/preliminary 10.00 / 10.00
Target Price Low / High 2.00 / 21.00
Median / STD DEV 10.00 / 5.96
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Sell Sell
rsi Sell Sell Sell
macd None ActivelyBuy None
stoch ActivelyBuy None None
ma20 ActivelyBuy Sell Sell
ma50 None None None
ma100 None Sell Sell
Candlestick PatternOct. 17, 2024 Bearish Harami - consists of an unusually large white body followed by a small black body contained within. Large white body It is considered as a bearish pattern when preceded by an uptrend.
ISIN US92332V1070
ceo Dr. Raju S. Mohan Ph.D.
Website https://ventyxbio.com
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.